According to a paper published in Alzheimer's Research & Therapy, prominent experts in the field of Alzheimer’s disease (AD) state that under current conditions, only a limited number of disease-modifying therapies have a chance to be approved and available to patients by 2025.
In "Drug Development in Alzheimer's Disease: The Path to 2025," the authors dissect the current realities and challenges of AD drug development and offer solutions to stimulate progress.
During the 2013 G8 Dementia Summit held in London, member nations established the goal to identify a disease-modifying therapy for dementia by 2025, setting the stage for coordinated global actions, including the initiation of the World Dementia Council. Many national policies or plans across the globe have also identified 2025 as the goal to effectively treat or prevent AD, including the US National Plan to Address Alzheimer's Disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze